AFP elevation

HMGA1 serves as a robust prognostic biomarker and functional driver of malignant progression in LIHC. Its integration into prognostic models may enhance risk stratification and guide personalized therapeutic strategies. Nevertheless, further in-vivo validation and prospective clinical studies are required to establish its translational applicability.

Next gene sequencing detected TP53 c.919+3del splice site variant and KRAS N116H. It is important to consider HMs when extramediastinal lesions or thrombocytopenia appear in patients with MGCT.

Patients with FALD face a non-negligible risk of developing HCC, thus supporting the need for surveillance. Elevated AFP levels at the time of FALD diagnosis may aid in risk stratification, which enables the targeted monitoring and early detection of HCC. Furthermore, routine surveillance contributes to the excellent prognosis of patients with FALD who develop HCC, thus making their prognosis comparable to that of patients without HCC.

Childhood malignant ovarian tumors are predominantly germ cell tumors, manifesting as large, solid-predominant, calcified lesions with high-risk ultrasound features. Ultrasonic, clinical, and laboratory features vary significantly by pathological type. Integrating these characteristics (including O-RADS and tumor markers) enables preoperative pathological diagnosis, supporting early multi-dimensional and personalized management.

Aggressive surgery does not improve survival when tumor markers normalize. Diagnostic delays remain common, emphasizing the need for improved awareness and referral systems in China.

While CA19-9 alone demonstrated limited predictive value, its combination with AFP improved prognostic accuracy. The study concludes that elevated serum AFP independently predicts adverse survival and recurrence outcomes in HBV-ICC patients after curative resection, and combining AFP with CA19-9 enhances prognostic stratification, supporting AFP as a practical biomarker for postoperative risk assessment.

We emphasize the importance of integrating tumor marker levels with imaging and histopathology for a multimodal diagnostic approach. Further research is needed to validate these associations to better define the role of biomarkers in HCC management.

Mendelian randomization analyses further supported a protective effect of higher RDH16 expression against HCC risk. These findings identify RDH16 as an immune-modulating biomarker in HCC, highlighting its potential role in shaping the tumor immune microenvironment and suggesting new avenues for personalized immunotherapeutic strategies.

Clinical and histopathologic factors consistently associated with NTR across studies include larger tumor size, multiple tumors, elevated alpha-fetoprotein levels, underlying liver fibrosis or cirrhosis, microvascular invasion, and satellite nodules-features that reflect aggressive tumor biology and impaired hepatic reserve. Improved preoperative risk stratification and identification of patients at high risk for NTR is essential to inform optimal treatment selection.

Targeted therapy with avapritinib and ruxolitinib was initiated but yielded limited response. Given the consistent co-occurrence of KIT mutations in previously reported similar cases, we propose the recognition of a distinct disease entity: ovarian germ cell tumor/mastocytosis with KIT mutations. This report emphasizes the importance of early genetic profiling and multidisciplinary collaboration in diagnosing and managing rare, genetically unified malignancies in pediatric oncology.

Although subsequent immunohistochemistry classified the case into the unfavorable prognostic subgroup, an individualized treatment strategy including three-drug combination chemotherapy based on the clinical suspicion of gastric cancer, targeted therapy with Apatinib, and localized radiotherapy, resulted in a remarkably long overall survival of 58 months...This case demonstrates that for CUP confined to lymph nodes, active and precisely reasoned individualized treatment can significantly improve prognosis, even in cases categorized as having an unfavorable prognosis. Furthermore, it underscores the necessity of immunohistochemistry for the accurate diagnosis of CUP and suggests that promoting precision medicine strategies may improve outcomes for these patients.

Addition of AFP, AFP-L3, and DCP to biannual US did not improve early-stage HCC detection. The trial was not adequately powered to provide evidence that the use of BMs aside from US plus AFP improves HCC surveillance. Establishing and validating alternative approaches to incorporation of BMs may improve surveillance methods for early-stage HCC detection.